local_hospital

Az Maria Middelares Gent

Address
lock Available on a paid plan

Oncology and Solid Tumor Research

At Az Maria Middelares Gent, the strongest activity is in oncology, with many studies focused on common and advanced cancers. Research covers breast cancer, non-small cell lung cancer, urothelial cancer, prostate cancer, ovarian cancer, and colorectal cancer, often aiming to test new treatments and improve outcomes for patients with difficult-to-treat disease.

  • Advanced and metastatic cancer care, including studies in lung, breast, ovarian, and urothelial cancers
  • Evaluation of newer cancer therapies designed to improve survival and disease control
  • Research in biomarker-guided and personalized treatment approaches for solid tumors

These trials reflect a broad effort to expand treatment options for both early and advanced neoplasms, with a strong focus on better disease control and longer-term benefit.

Breast Cancer and Women’s Oncology

The site is active in breast cancer research, including HER2-positive, hormone receptor-positive, and triple negative breast cancer. Studies also include early-stage and metastatic disease, with the goal of improving treatment effectiveness and refining care after surgery or in advanced settings.

  • Testing new treatment combinations for HER2-positive and HER2-expressing breast cancer
  • Studies in early-stage breast cancer to reduce recurrence risk after surgery
  • Trials for metastatic and high-risk disease aimed at improving disease-free and progression-free survival

This area of research supports more personalized care for patients with breast neoplasms, especially where standard options may be limited or need improvement.

Urologic Cancers and Genitourinary Oncology

Another major focus is urothelial carcinoma, including bladder cancer in non-muscle-invasive, muscle-invasive, locally advanced, and metastatic forms. The site also studies prostate cancer, including castration-sensitive and castration-resistant disease, with trials designed to improve treatment response and delay progression.

  • Bladder cancer studies exploring better local and systemic treatment strategies
  • Prostate cancer trials assessing therapies for advanced and recurrent disease
  • Research into treatment options for patients with biomarker-defined or high-risk genitourinary cancers

These studies aim to improve outcomes in genitourinary malignancies through more effective and targeted approaches.

Gastroenterology and Liver Disease

Clinical research at the site also includes inflammatory bowel disease and chronic liver disease. Trials involve Crohn’s disease, ulcerative colitis, NASH, and MASH, with a focus on controlling inflammation, protecting liver function, and improving long-term disease management.

  • Studies in Crohn’s disease and ulcerative colitis aimed at better symptom and inflammation control
  • Liver disease research in NASH and MASH to assess disease improvement and prevent progression
  • Work on complications of cirrhosis, including prevention of esophageal varices

This portfolio shows a strong interest in both digestive system diseases and metabolic liver disorders, with the goal of improving everyday care and long-term outcomes.

Cardiovascular and Metabolic Research

The site participates in studies on cardiovascular disease, atherosclerotic disease, heart failure, aortic valve disease, and hypertension. Several trials also address elevated lipoprotein(a) and overall risk reduction, reflecting a focus on preventing major cardiac and vascular events.

  • Trials testing strategies to reduce stroke, heart attack, and other cardiovascular complications
  • Research in blood pressure control, including difficult-to-treat hypertension
  • Studies in valve disease and cardiac surgery aimed at improving patient recovery and safety

At Az Maria Middelares Gent, this area connects prevention, treatment optimization, and better management of chronic circulatory disorders.

Respiratory, Immune, and Inflammatory Conditions

Research also extends to non-small cell lung cancer, small cell lung cancer, COPD, asthma, and pneumonia, alongside immune-mediated disorders such as psoriasis and spondyloarthritis. These trials often aim to improve treatment effectiveness, safety, or disease control in conditions that can significantly affect daily life.

  • Respiratory studies in lung cancer, COPD, asthma, and severe pneumonia
  • Immune and inflammatory disease trials in psoriasis and arthritis-related conditions
  • Research focused on reducing symptoms and improving quality of life in chronic disease

This mix of studies highlights the site’s broader interest in immune system processes and respiratory tract diseases, beyond its core cancer program.

Site Overview

assignment
154
connected trials
corporate_fare
64
sponsors
science
226
IMPs

Activity Indicator

Last 6 months

19
Trials started
+58% vs previous period.
12
Trials started 6–12 months ago
154
Total trials linked
Highly Active
trending_upGrowing+58%
2
5
2
7
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 24 therapeutic areas and 15 of 226 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 211 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
80
Sponsors (total)
64
Active sponsors
42

Sponsor Network

Top 42 by active trials.

lock +41 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +23 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 307 other sites in Belgium

description
Trial volume
154
Outperforms 95% of sites
public
Therapeutic diversity
25areas
Outperforms 97% of sites
groups
Sponsor diversity
64sponsors
Outperforms 94% of sites

Therapeutic Area Benchmark — Belgium

Select a therapeutic area to compare against other sites in Belgium.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Belgium

Market Share

Country: Belgium

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Az Maria Middelares Gent

lock Showing 1 of 154 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancerBayer AG, Bayer Consumer Care AGPhase IIINot RecruitingOct 2023

IMP list

lock Showing 1 of 226 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Carboplatin27Unknown2018-12-182026-05-18

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.